Search details
1.
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Lancet Oncol
; 23(11): 1430-1440, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36244398
2.
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Oncologist
; 27(11): 905-e848, 2022 11 03.
Article
in English
| MEDLINE | ID: mdl-36156099
3.
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels.
Ann Surg Oncol
; 2022 Jan 05.
Article
in English
| MEDLINE | ID: mdl-34988836
4.
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Oncologist
; 26(10): e1704-e1729, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34288262
5.
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy.
Ann Surg Oncol
; 28(8): 4433-4443, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33420565
6.
Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.
Ann Surg Oncol
; 28(3): 1777-1785, 2021 Mar.
Article
in English
| MEDLINE | ID: mdl-32892267
7.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol
; 21(5): 671-684, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32203698
8.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(6): 796-807, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32416072
9.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32653053
10.
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Cancer
; 125(10): 1629-1636, 2019 05 15.
Article
in English
| MEDLINE | ID: mdl-30645764
11.
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.
Oncologist
; 24(4): 475-482, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30470690
12.
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Oncologist
; 24(10): 1340-1347, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31040255
13.
FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.
Oncologist
; 24(11): 1462-1468, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31249137
14.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Gastric Cancer
; 22(4): 828-837, 2019 07.
Article
in English
| MEDLINE | ID: mdl-30911859
15.
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Future Oncol
; 14(5): 417-430, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29094609
16.
Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution.
Proc Natl Acad Sci U S A
; 112(47): E6496-505, 2015 Nov 24.
Article
in English
| MEDLINE | ID: mdl-26561581
17.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(11): 1467-1482, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28958504
18.
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Cancer
; 123(6): 1061-1070, 2017 05 15.
Article
in English
| MEDLINE | ID: mdl-27926778
19.
ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels.
Ann Surg Oncol
; 29(Suppl 3): 616-617, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-35930113
20.
A subgroup cluster-based Bayesian adaptive design for precision medicine.
Biometrics
; 73(2): 367-377, 2017 06.
Article
in English
| MEDLINE | ID: mdl-27775814